These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 23931954)
21. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. Baldwin CM; Keating GM CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483 [TBL] [Abstract][Full Text] [Related]
22. Transdermal rotigotine (Neupro) for Parkinson's disease. Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291 [No Abstract] [Full Text] [Related]
24. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. Kassubek J; Chaudhuri KR; Zesiewicz T; Surmann E; Boroojerdi B; Moran K; Ghys L; Trenkwalder C BMC Neurol; 2014 Mar; 14():42. PubMed ID: 24602411 [TBL] [Abstract][Full Text] [Related]
25. Rotigotine Transdermal Patch: A Review in Parkinson's Disease. Frampton JE CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728 [TBL] [Abstract][Full Text] [Related]
26. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066 [TBL] [Abstract][Full Text] [Related]
27. Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study. Isaacson SH; Boroojerdi B; Waln O; McGraw M; Kreitzman DL; Klos K; Revilla FJ; Heldman D; Phillips M; Terricabras D; Markowitz M; Woltering F; Carson S; Truong D Parkinsonism Relat Disord; 2019 Jul; 64():132-137. PubMed ID: 30948242 [TBL] [Abstract][Full Text] [Related]
28. Rotigotine transdermal patch for the treatment of Parkinson's Disease. Perez-Lloret S; Rey MV; Ratti PL; Rascol O Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B; Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486 [TBL] [Abstract][Full Text] [Related]
31. Clinical studies with transdermal rotigotine in early Parkinson's disease. Poewe W; Luessi F Neurology; 2005 Jul; 65(2 Suppl 1):S11-4. PubMed ID: 16030290 [No Abstract] [Full Text] [Related]
33. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials. Wang HT; Wang L; He Y; Yu G J Neurol Sci; 2018 Oct; 393():31-38. PubMed ID: 30099246 [TBL] [Abstract][Full Text] [Related]
34. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage. Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886 [TBL] [Abstract][Full Text] [Related]
36. Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Nomoto M; Mizuno Y; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N J Neurol; 2014 Oct; 261(10):1887-93. PubMed ID: 25022939 [TBL] [Abstract][Full Text] [Related]
37. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K; Lyons KE Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805 [TBL] [Abstract][Full Text] [Related]
39. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease]. Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158 [TBL] [Abstract][Full Text] [Related]
40. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study. Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]